LLYLilly (Eli)
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for ~19% a year FCF growth. The price demands less than its three-year revenue growth of 39% a year, expectations look modest.
In its normal range: P/E 39.5 vs a 37.1 median over 39 quarters (+6% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What LLY's price assumes
Lilly (Eli) trades at 39.5× earnings against 26.2× for the median Drug Manufacturers - General name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - General median 26.2 · 1.51× the median: the market pays up for this one
- Price / sales
- 12.3
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 1.9%
Free cash flow yield · Drug Manufacturers - General median 5.7%
- Growth the price implies
- +19%
Growth the price implies · The price pays for +19% free cash flow growth a year for a decade; the business has delivered +70% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 28.9
- EV / salestoday's price, trailing year to Jun 30, 2026
- 12.9
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - General median P/E16 names
- 26.2
- Free cash flow, trailing twelve months
- $18.2B
- Market capitalisation
- $979.6B
- 3-year revenue growth
- +39%
- 3-year free cash flow growth
- +70%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $825.53 |
| Its own P/E history, median | $1,107.01 |
| Its own P/E history, upper quartile | $1,745.67 |
| 52-week range | $711.13 – $1,279.81 |
| Today | $1,178.51 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, General
The closest names by size in the same industry